In conclusion, our results indicate that maintenance of hepatic GSTA1 levels leads to a decrease in FABP1 levels, thereby improving hepatic steatosis, which represents an interesting approach for exploring GSTA1 stabilizers or enhancers as a new class of drugs against MASLD in the future. This evidence concerns the gene FABP1 and Hepatic steatosis.